Johnson & Johnson at UBS Global Healthcare Conference: Vision Business Focus

Johnson & Johnson (JNJ) detailed its strategic vision for its vision segment at the UBS Global Healthcare Conference 2025, highlighting strong Q3 2023 operational growth of 6%, with surgical vision up 13%. The company's growth strategy centers on disruptive innovation, global expansion of products like the Acuvue MAX Family and Tecnis Odyssey/Purity, and data-driven decision-making, including leveraging AI across R&D, supply chain, and sales. JNJ is focused on increasing premiumization in cataract surgery, which now constitutes 20% of procedures, and aims for above-market performance, noting the vision business's resilience to macroeconomic factors and its ability to manage pricing pressures in markets like China through volume growth.

Analysis

Johnson & Johnson's vision segment demonstrated robust performance in Q3 2023, achieving 6% operational growth, significantly bolstered by a 13% increase in surgical vision. The company's strategic vision, outlined at the UBS Global Healthcare Conference 2025, emphasizes disruptive innovation, global expansion of products like the Acuvue MAX Family and Tecnis Odyssey/Purity, and data-driven decision-making to secure above-market growth. This focus is critical as the vision business, split 70% contact lenses and 30% surgical, is a key strategic area for the broader J&J enterprise.

J&J is actively driving premiumization in cataract surgery, with premium lenses now accounting for 20% of procedures, and Tecnis Odyssey identified as the fastest-growing PCIOL in the U.S. The company has successfully navigated pricing pressures in markets such as China by increasing volume, demonstrating adaptability. Management also highlighted the vision business's inherent resilience to macroeconomic factors, attributing it to the essential nature of sight.

Significant investment in artificial intelligence (AI) is being leveraged across the supply chain, R&D, and sales force to enhance efficiency and accelerate innovation. J&J's R&D agenda is focused on advanced optics and addressing unmet needs, with an openness to inorganic growth opportunities and expansion beyond traditional vision correction. This comprehensive approach underscores a commitment to sustained growth and market leadership within the vision care sector.

Key Decisions for Investors

• Investors should closely monitor the global adoption rates and sales trajectory of J&J's premium vision products, such as the Acuvue MAX Family and Tecnis Odyssey/Purity, as these are key drivers for continued above-market growth.
• Evaluate the ongoing integration and impact of AI across J&J's vision operations, as successful implementation could lead to enhanced R&D efficiency, optimized supply chains, and improved commercialization, ultimately boosting profitability.
• Consider the vision segment's demonstrated resilience to macroeconomic headwinds and its strategic approach to managing pricing pressures in international markets as a stabilizing factor within JNJ's diversified portfolio.